

Edgar Filing: NOVADEL PHARMA INC - Form 8-K

NOVADEL PHARMA INC  
Form 8-K  
May 11, 2004

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)  
OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) MAY 10, 2004  
-----

NOVADEL PHARMA INC.  
-----

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

DELAWARE  
-----

000-23399

22-2407152  
-----

(STATE OR OTHER  
JURISDICTION OF  
FORMATION)

(COMMISSION  
FILE NUMBER)

(IRS EMPLOYER  
IDENTIFICATION NO.)

25 MINNEAKONING RD.  
-----

FLEMINGTON, NJ

08822  
-----

(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

(ZIP CODE)

REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE (908) 782-3431  
-----

-----  
(FORMER NAME OR FORMER ADDRESS, IF CHANGES SINCE LAST REPORT)

ITEM 5. OTHER EVENTS.  
-----

On May 10, 2004, Novadel Pharma Inc., a Delaware corporation (the "Company"), announced that its common stock is expected to begin trading on the American Stock Exchange LLC ("AMEX") on Tuesday, May 11, 2004 under the symbol "NVD". In connection with the listing, the Company filed a Registration Statement on Form 8-A with the Securities and Exchange Commission.

Item 7. Financial Statements and Exhibits.  
-----

Set forth below is a list of Exhibits included as part of this Current Report.

Edgar Filing: NOVADEL PHARMA INC - Form 8-K

99 Press Release of the Company dated May 10, 2004.

ITEM 9. REGULATION FD DISCLOSURE.  
-----

Exhibit 99 hereto sets forth a press release issued by the Company to report the acceptance for listing on the AMEX and additional information about the Company.

SIGNATURES  
-----

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly authorized and caused the undersigned to sign this Report on the Registrant's behalf.

NOVADEL PHARMA INC.

By: /s/ Gary A. Shangold, M.D.  
-----

Name: Gary A. Shangold, M.D.  
Title: President and Chief Executive  
Officer

Dated: May 10, 2004